SB273005 是一種有效的integrin抑制劑，對(duì)αvβ3 受體和αvβ5受體的K_i分別為1.2 nM 和 0.3 nM。In vitro, SB273005 inhibits human osteoclast-mediated bone resorption with IC50 of 11 nM. In blood containing MDA-MB-231 cells, a combination of SB273005 and lamifiban inhibits tumor cell adhesion to vascular extracellular matrix (ECM).In rat models of bone resorption and osteoporosis, SB273005 (30 mg/kg, p.o.) inhibits the parathyroid hormone-stimulated calcemic response, and inhibits bone loss. In rat with adjuvant-induced arthritis, SB273005 (60 mg/kg, p.o.) significantly reduces the symptoms of adjuvant-induced arthritis. SB273005 (1000 mg/kg/day, p.o.) causes acute, transient necrosis of vascular smooth muscle cell (VSMC) in aorta and renal arteries of mice. In pregnant mice, SB273005 reverses the reduction of Th1 cell-produced IL-2 levels and the increase of Th2 cell-derived IL-10 levels.SB273005 是一種有效的integrin抑制劑，對(duì)αvβ3 受體和αvβ5受體的Ki分別為1.2 nM 和 0.3 nM。

Target	Value
αvβ5 receptor (Cell-free assay)	0.3 nM
αvβ3 receptor (Cell-free assay)	1.2 nM

在體外，SB273005抑制人破骨細(xì)胞介導(dǎo)的骨吸收，IC50 為11 nM。在包含MDA-MB-231細(xì)胞的血液中，SB273005與lamifiban結(jié)合抑制腫瘤細(xì)胞粘附到血管細(xì)胞外基質(zhì)上(ECM)。

在骨吸收和骨質(zhì)疏松大鼠模型中，SB273005 (30 mg/kg, p.o.)抑制甲狀旁腺素刺激的血鈣反應(yīng)，并抑制骨損失。在佐劑性關(guān)節(jié)炎大鼠體內(nèi)，SB273005 (60 mg/kg, p.o.)顯著減少佐劑誘導(dǎo)的關(guān)節(jié)炎癥狀。 在大鼠主動(dòng)脈和腎動(dòng)脈中，SB273005 (1000 mg/kg/day, p.o.)引起血管平滑肌細(xì)胞(VSMC)急性暫時(shí)性壞死。在懷孕的小鼠體內(nèi)，SB273005逆轉(zhuǎn)Th1細(xì)胞產(chǎn)生的IL-2 l水平的下降，以及Th2細(xì)胞衍生的IL-10水平的增加。